NCT01522547 Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease Status COMPLETED Phase PHASE1
NCT01497093 Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Status COMPLETED Phase PHASE1
NCT01495598 Pomalidomide for Kaposi Sarcoma in People With or Without HIV Status COMPLETED Phase PHASE1/PHASE2
NCT01474330 A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects Status COMPLETED Phase PHASE1
NCT01464034 A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Status TERMINATED Phase PHASE1/PHASE2
NCT01432600 Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide Status COMPLETED Phase PHASE1/PHASE2
NCT01421186 A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma Status COMPLETED Phase PHASE1/PHASE2
NCT01324947 Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma Status COMPLETED Phase PHASE3
NCT01319422 Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma Status COMPLETED Phase PHASE2
NCT01311687 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study Status COMPLETED Phase PHASE3
NCT01212952 Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Status COMPLETED Phase PHASE1/PHASE2
NCT01198067 Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia Status TERMINATED Phase PHASE1
NCT01178281 Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Status COMPLETED Phase PHASE3
NCT01177735 Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma Status COMPLETED Phase PHASE2
NCT01159574 Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma Status COMPLETED Phase PHASE2
NCT01078974 Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia Status TERMINATED Phase PHASE1
NCT00949364 Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage Status COMPLETED Phase PHASE2
NCT00833833 MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Status COMPLETED Phase PHASE1/PHASE2
NCT00717522 Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma Status TERMINATED Phase PHASE2